Staff Reports
President Donald Trump reportedly has signed off on a plan to remove FDA Commissioner Marty Makary after a wave of harsh coverage and industry complaints. The move marks a dramatic moment for the agency charged with protecting Americans’ health. But before anyone pops the champagne or hands out blame, we should ask: who’s really running the show — scientists at the FDA, or talking heads and corporate investors?
The sudden pile-on
What changed was not one big scandal but a pile-up. Investigative features and opinion pages questioned Commissioner Marty Makary’s leadership. A high‑profile rejection of Replimune’s RP1 therapy for melanoma became the flashpoint. Industry warnings about layoffs, stock drops, and editorials calling for action created a storm. Then word leaked that HHS pressure and media heat pushed the White House toward an ouster — and President Donald Trump reportedly gave the nod.
The real issue: science versus sales
Here’s the part the loudest critics skip: the FDA’s job is to judge evidence, not bow to headlines. Makary defended the agency, saying he works for the American people and stands by FDA scientists. Many companies push for approvals based on slim data because it helps their stock prices and investor returns. That can create real harm if ineffective or unsafe treatments reach patients. If the agency caves every time a newspaper and a hedge fund complain, what’s left of independent review?
Politics masquerading as medicine
We’ve also seen political forces crowd the conversation. Secretary Robert F. Kennedy Jr. and HHS officials reportedly weighed in, and conservative or industry groups amplified complaints. That makes a messy stew of motives: patient advocates, investors, political allies, and media editors all stirring in different directions. When internal churn and departures at the FDA get spun into a narrative of “chaos,” the public loses trust — and the easiest fix becomes firing the messenger instead of addressing the root problems.
Don’t throw the agency under the bus
If President Donald Trump goes through with a removal, it will look like capitulation to pressure rather than leadership. The better approach is to defend scientific independence while fixing real management issues inside the FDA. Tighten transparency. Reward good science. Insist on standards that protect patients and also speed safe, effective therapies to market. The fight over Marty Makary should be about that sensible middle ground — not a public purge staged to make the headlines go away.
